MedTrace Logo

Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer

NCT00535509 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2015-12-17

No results posted yet for this study

Summary

Phase II trial of Neoadjuvant \[FEC100\]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer

Conditions

Interventions

RADIATION

Cisplatin-Docetaxel ± Trastuzumab

Chemo \& RT

OTHER

Cisplatin-Docetaxel ± Trastuzumab

Chemo \& RT

DRUG

Cisplatin-Docetaxel ± Trastuzumab

Chemo \& RT

Sponsors & Collaborators

  • King Faisal Specialist Hospital & Research Center

    lead OTHER

Principal Investigators

  • Taher Twegieri, MD · KFSH&RC

  • Dahish Ajarim, MD · KFSH&RC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2013-06-30
Completion
2013-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00535509 on ClinicalTrials.gov